MedPath

An Exploratory RWE Study Exploring Effects of a Goat Milk Based Young Child Formula on Health Benefits

Not Applicable
Recruiting
Conditions
Healthy Children
Interventions
Dietary Supplement: Goat-milk Based Formula
Registration Number
NCT06287385
Lead Sponsor
Danone Nutricia
Brief Summary

This is an exploratory real-world study designed to gain insight into the role of the product in terms of health benefits in toddlers, with the potential to generate hypotheses on key and other exploratory objectives.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
120
Inclusion Criteria
  1. Age between 1-2 years of age
  2. Healthy term infants, gestational ages 37~42 weeks
  3. Birth weight within normal range for gestational age and sex (10th to 90th percentile of the Chinese Child Growth Chart);
  4. Normal weight, height at screening (10th to 90th percentile of the Chinese Child Growth Chart)
  5. Chinese population;
  6. Subjects whose parents/guardians are intending to goat formula feed according to protocol during the study period;
  7. Informed consent from one parent or legal representative;
  8. Subjects whose parents/guardians are adults, have sufficient ability in Chinese to complete informed consent and other study documents;
  9. Subjects whose parents/guardians are able to use smart phone with cameras; install and use a secure WeChat platform on the mobile phone during the study period; connect to the network through the mobile phone; take photos to record stool; complete questionnaires;
  10. Subjects whose parents/guardians can be directly contacted by telephone or WeChat throughout the study.
Exclusion Criteria
  1. Probiotics or probiotics-supplemented products use within 4 weeks prior to enrolment;
  2. Goat-milk based formula or fresh goat milk use within 4 weeks prior to enrolment;
  3. Special infant formula use within 4 weeks prior to enrolment, including but not limited to hydrolysed infant formula, lactose-free infant formula and anti-reflux infant formula etc.;
  4. Known allergy to milk products or soy product;
  5. Medially diagnosed disorders requiring a special diet, including but not limited to reflux esophagitis, phenylketonuria etc;
  6. Significant congenital abnormality or other health conditions that could affect the outcome measurements;
  7. Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements;
  8. Participation in any other studies involving investigational or marketed products concomitantly or within 4 weeks prior to entry into the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Formula fedGoat-milk Based FormulaGoat-milk Based Formula (Stage 3)
Primary Outcome Measures
NameTimeMethod
Stool characteristicsbefore and 7, 14, 21 and 28 days after administration of the investigational product

Stool characteristics assessed with BITSS

Secondary Outcome Measures
NameTimeMethod
Quality of life of subjectsbefore and 28 days after administration of the investigational product

Quality of life of subjects assessed with Pediatric Quality of Life Inventory (PedsQL)

Lifestyle-related immune indicatorsbefore and 28 days after administration of the investigational product

Lifestyle-related immunity status reported by parents or medically diagnosed (indicated in the subject's medical file)

Gastrointestinal symptomsbefore and 7, 14, 21 and 28 days after administration of the investigational product

Gastrointestinal symptoms assessed with Gastrointestinal Symptom Questionnaire

Trial Locations

Locations (1)

Peking University Third Hospital

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath